According to their findings, it's the same nerve cells in our brain that give us a feeling of being full after a meal that also make us crave sweet things.In the study, the researchers led by Henning ...

A bill aiming to make opioid treatment programs unlawful was introduced into the West Virginia Senate last week.

No. 2 / 2025Zealand Pharma Announces Financial Results for the Full Year 2024A transformational year with significant ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...

Who hasn't been there? The big meal is over, you're full, but the craving for sweets remains. Researchers from the Max Planck ...

New research sheds light on how ketamine affects the brain by targeting a specific NMDA receptor subtype, GluN1-2B-2D.

Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...

Who hasn't been there? The big meal is over, you're full, but the craving for sweets remains. Researchers have now discovered that what we call the 'dessert stomach' is rooted in the brain. The same ...

In mice, the neurons that dictate the feeling of being full are also the ones that cause sugar cravings, potentially ...

Excluding people with type 2 diabetes from the trial might have resulted in a missed opportunity to establish whether people with both Parkinson's disease and type 2 diabetes could benefit from GLP-1 ...

HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online Jan. 16 ...